ロード中...
Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant models
PURPOSE: PARP inhibition (PARPi) has modest clinical activity in recurrent BRCA mutant (BRCA(MUT)) high-grade serous ovarian cancers (HGSOC). We hypothesized that PARPi increases dependence on ATR/CHK1 such that combination PARPi with ATR/CHK1 blockade results in increased cell death and tumor regre...
保存先:
| 出版年: | Clin Cancer Res |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5474193/ https://ncbi.nlm.nih.gov/pubmed/27993965 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2273 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|